跳至主要内容
临床试验/NCT04664088
NCT04664088Unknown不适用

The Efficacy and Safety of Acupuncture for Prophylaxis of Vestibular Migraine

Affiliated Hospital of Jiaxing University1 个研究点 分布在 1 个国家目标入组 72 人开始时间: 2021年1月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
发起方
入组人数
72
试验地点
1
主要终点
Change in the number of vertigo/migraine days and vertigo/migraine attacks

研究概览

简要总结

With its high incidence rate and low diagnosis rate, vestibular migraine (VM) can seriously affect patients' quality of life. Current treatment of VM mainly contain rescue treatment and prophylaxis, both of which are often pharmacological-based therapies and bring a series of unavoidable side effects, which leads to poor compliance of patients. Moreover, frequent VM attacks can seriously affect patients' daily life and work. Therefore, prophylaxis treatment is of great significance for VM patients. As a non-pharmarceutical therapy, acupuncture is widely used for a wide range of migrainous and emotional disorders. Thus, it might be an alternative treatment for VM, but current evidence remains inconclusive. The aim of this randomized controlled trial is to investigate the prophylactic efficacy and safety of acupuncture therapy in patients with VM.

详细描述

This randomized controlled trial will enroll patients with vestibular migraine from the First Affiliated Hospital of Jiaxing University. All participants will be randomly assigned to two groups. Participants will receive acupuncture in the treatment group, while participants in the control group will be treated by venlafaxine. All treatments will be given for 8 weeks. The primary outcome measures are change in vertigo/migraine days and vertigo/migraine attacks, vertigo severity, and migraine intensity per 4 weeks from baseline. The secondary outcome measures are change in dosage of rescue medication, anxiety level,depression level,and quality of life per 4 weeks from baseline.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with age 18 to 80 , male or female;
  • Patients meet the criteria proposed by the collaboration of Barany Society and the International Headache Society in 2012;
  • Vertigo/migraine attacks at least 3 times per month in the last 3 months; or vertigo/migraine days are at least 4 days per month;
  • Patients have unsatisfactory response to rescue treatments and seek for preventive treatments;
  • Patients can fully understand the study protocol and agree to sign written informed consent forms.

排除标准

  • Patients'vertigo and headache are caused by other diseases, such as vestibular neuritis, Meniere disease, tension headache, and other cerebrovascular diseases.
  • Patients have prophylactic headache treatment with drugs in the past 3 months.
  • Patients are receiving adjunctive therapy that is not widely accepted for treating VM, such as Chinese herbs.
  • Patients have severe complications in cardiovascular, cerebrovascular, liver, kidney, hematopoietic and other systems that are not controlled significantly;
  • Pregnant and lactating female patients;
  • Patients have mental illness that affects cognitive function.

研究组 & 干预措施

Acupuncture group

Experimental

Patients in this group will receive acupuncture once every other day (3 days per week) over an 8-week period (a total of 24 sessions).

干预措施: Acupuncture (Procedure)

Medication group

Active Comparator

Participants in this group will receive oral administration of venlafaxine 50 mg once a day for 8 weeks.

干预措施: Venlafaxine (Drug)

结局指标

主要结局

Change in the number of vertigo/migraine days and vertigo/migraine attacks

时间窗: 4 weeks before intervention, at 4, 8 weeks after intervention and at 4, 8, 16 weeks of follow-up

The number of vertigo/migraine days and vertigo/migraine attacks will be assessed by a patient diary.

Change in vertigo severity

时间窗: 4 weeks before intervention, at 4, 8 weeks after intervention and at 4, 8, 16 weeks of follow-up

Vertigo severity will be measured by dizziness handicap inventory (DHI)

Change in migraine intensity

时间窗: 4 weeks before intervention, at 4, 8 weeks after intervention and at 4, 8, 16 weeks of follow-up

Migraine intensity will be measured by visual analogue scale (VAS)

次要结局

  • Change in anxiety level(4 weeks before intervention, at 4, 8 weeks after intervention and at 4, 8, 16 weeks of follow-up)
  • Change in depression level(4 weeks before intervention, at 4, 8 weeks after intervention and at 4, 8, 16 weeks of follow-up)
  • Change in quality of life(4 weeks before intervention, at 4, 8 weeks after intervention and at 4, 8, 16 weeks of follow-up)
  • Change in doses of rescue medication(4 weeks before intervention, at 4, 8 weeks after intervention and at 4, 8, 16 weeks of follow-up)

研究者

发起方
Affiliated Hospital of Jiaxing University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Tianye Hu

doctor

Affiliated Hospital of Jiaxing University

研究点 (1)

Loading locations...

相似试验